OncoMatch/Clinical Trials/NCT05785039
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Is NCT05785039 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies BL-B01D1 for urinary system tumor.
Treatment: BL-B01D1 — Phase IIa/IIb clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors such as locally advanced or metastatic urinary system tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard treatment
after failure or intolerance to standard treatment or for which standard treatment is currently unavailable or unavailable
Cannot have received: antineoplastic therapy
Antineoplastic therapy within 4 weeks or 5 half-lives before the first dose
Cannot have received: mitomycin (mitomycin)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: nitrosourea (nitrosoureas)
Mitomycin and nitrosoureas were administered within 6 weeks before the first dose
Cannot have received: oral fluorouracil drugs
Oral fluorouracil drugs
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, left ventricular ejection fraction 50%
No severe cardiac dysfunction, left ventricular ejection fraction 50%; With adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05785039 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antineoplastic therapy, mitomycin, nitrosourea disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify